Graduate School of Hebei Medical University, Shijiazhuang, Hebei, China.
Department of Neurology, Hebei General Hospital, No. 348 21 Heping West Road, Shijiazhuang, 050051, Hebei, China.
Mol Brain. 2024 Jul 29;17(1):48. doi: 10.1186/s13041-024-01119-0.
Stroke is a significant global burden, causing extensive morbidity and mortality. In metabolic states where glucose is limited, ketone bodies, predominantly β-hydroxybutyrate (BHB), act as alternative fuel sources. Elevated levels of BHB have been found in the ischemic hemispheres of animal models of stroke, supporting its role in the pathophysiology of cerebral ischemia. Clinically, higher serum and urinary BHB concentrations have been associated with adverse outcomes in ischemic stroke, highlighting its potential utility as a prognostic biomarker. In both animal and cellular models, exogenous BHB administration has exhibited neuroprotective effects, reduction of infarct size, and improvement of neurological outcomes. In this review, we focus on the role of BHB before and after ischemic stroke, with an emphasis on the therapeutic potential and mechanisms of ketone administration after ischemic stroke.
中风是一个重大的全球负担，导致广泛的发病率和死亡率。在葡萄糖有限的代谢状态下，酮体，主要是β-羟丁酸（BHB），作为替代燃料来源。在中风动物模型的缺血半球中发现了升高的 BHB 水平，支持其在脑缺血病理生理学中的作用。临床上，较高的血清和尿 BHB 浓度与缺血性中风的不良结局相关，突出了其作为预后生物标志物的潜在效用。在动物和细胞模型中，外源性 BHB 给药表现出神经保护作用，减少梗死面积，并改善神经功能结局。在本综述中，我们重点关注缺血性中风前后的 BHB 作用，强调缺血性中风后酮体给药的治疗潜力和机制。
